IKNA Ikena Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IKNA

Price (delayed)

$1.32

Market cap

$63.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.63

Enterprise value

-$45.46M

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that ...

Highlights
IKNA's quick ratio has surged by 69% year-on-year and by 21% since the previous quarter
IKNA's equity is up by 16% year-on-year and by 9% since the previous quarter
The debt has soared by 89% YoY but it has contracted by 7% from the previous quarter
Ikena Oncology's revenue has decreased by 41% YoY and by 34% QoQ
IKNA's gross profit is down by 41% YoY and by 34% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ikenaoncology.com
Peers: OMER OMGA

Key stats

What are the main financial stats of IKNA
Market
Shares outstanding
48.26M
Market cap
$63.7M
Enterprise value
-$45.46M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
6.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.96
Earnings
Revenue
$9.16M
EBIT
-$68.33M
EBITDA
-$65.59M
Free cash flow
-$80.16M
Per share
EPS
-$1.63
Free cash flow per share
-$1.92
Book value per share
$3.52
Revenue per share
$0.22
TBVPS
$4.6
Balance sheet
Total assets
$192.09M
Total liabilities
$22.34M
Debt
$10.74M
Equity
$169.76M
Working capital
$164.46M
Liquidity
Debt to equity
0.06
Current ratio
12.58
Quick ratio
12.35
Net debt/EBITDA
1.66
Margins
EBITDA margin
-716.1%
Gross margin
100%
Net margin
-744.2%
Operating margin
-823.3%
Efficiency
Return on assets
-37.3%
Return on equity
-44.2%
Return on invested capital
-75.2%
Return on capital employed
-38.4%
Return on sales
-745.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IKNA stock price

How has the Ikena Oncology stock price performed over time
Intraday
0%
1 week
1.54%
1 month
-1.12%
1 year
-77.32%
YTD
-32.99%
QTD
-7.04%

Financial performance

How have Ikena Oncology's revenue and profit performed over time
Revenue
$9.16M
Gross profit
$9.16M
Operating income
-$75.42M
Net income
-$68.17M
Gross margin
100%
Net margin
-744.2%
Ikena Oncology's operating margin has plunged by 81% YoY and by 67% from the previous quarter
The net margin has plunged by 69% YoY and by 65% from the previous quarter
Ikena Oncology's revenue has decreased by 41% YoY and by 34% QoQ
IKNA's gross profit is down by 41% YoY and by 34% QoQ

Growth

What is Ikena Oncology's growth rate over time

Valuation

What is Ikena Oncology stock price valuation
P/E
N/A
P/B
0.38
P/S
6.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.96
IKNA's EPS is up by 14% year-on-year
The stock's price to book (P/B) is 62% less than its last 4 quarters average of 1.0
IKNA's equity is up by 16% year-on-year and by 9% since the previous quarter
The P/S is 44% lower than the last 4 quarters average of 10.8
Ikena Oncology's revenue has decreased by 41% YoY and by 34% QoQ

Efficiency

How efficient is Ikena Oncology business performance
IKNA's return on sales has dropped by 69% year-on-year and by 66% since the previous quarter
Ikena Oncology's ROIC has decreased by 38% YoY and by 17% from the previous quarter
IKNA's return on assets is down by 9% year-on-year and by 6% since the previous quarter
Ikena Oncology's ROE has decreased by 8% YoY and by 4.5% from the previous quarter

Dividends

What is IKNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IKNA.

Financial health

How did Ikena Oncology financials performed over time
IKNA's current ratio has soared by 69% YoY and by 21% QoQ
IKNA's quick ratio has surged by 69% year-on-year and by 21% since the previous quarter
The debt is 94% less than the equity
The debt has soared by 89% YoY but it has contracted by 7% from the previous quarter
Ikena Oncology's debt to equity has surged by 50% YoY but it has decreased by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.